Physician profile
Mary Crow
NPI 1538280961
$84,854.06
in general payments reported to CMS, 2019-2025
11 companies · $2,303 in 2025
The $2,303 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $2,525 · 2021: $22K · 2022: $24K · 2023: $13K · 2024: $3,525 · 2025: $2,303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $15K · Honoraria: $1,691 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,250 · Travel and Lodging: $465 · Food and Beverage: $210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,279.50 |
| Honoraria | $1,691.25 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,250.00 |
| Travel and Lodging | $464.90 |
| Food and Beverage | $209.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $33,907.91 | 2019-2023 | |
| Astrazeneca Uk Limited | $24,398.75 | 2021-2022 | |
| Glaxosmithkline, LLC. | $12,575.00 | 2021-2024 | Benlysta |
| Gilead Sciences, INC. | $4,291.92 | 2019-2021 | |
| Astrazeneca Ab | $2,790.00 | 2022 | |
| Autolus INC | $1,691.25 | 2025 | |
| Biogen, INC. | $1,542.00 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $1,395.00 | 2023 | Saphnelo |
| Genzyme Corporation | $1,250.00 | 2024 | |
| Novartis Pharmaceuticals Corporation | $612.23 | 2025 | |
| Kyowa Kirin Co., LTD | $400.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Crow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.